ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Evaluating the association of apolipoprotein E genotype and cognitive resilience in SuperAgers.
Abstract read
In one paragraph
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- SuperAging is not the inverse of common-variant Alzheimer's risk: evidence across genetic ancestries.Alzheimer's research & therapy · 2026Article
- Error unawareness as a driver of cognitive decline in individuals at risk for Alzheimer's disease.Communications biology · 2026Article
- Evaluating the association of apolipoprotein E genotype and cognitive resilience in SuperAgers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
Corrections and comments
- Update of
Authors and funding
39 authors.
Alaina DurantVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Shubhabrata MukherjeeDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Michael L LeeDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Seo-Eun ChoiDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Phoebe ScollardDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Brandon S KlinedinstDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Emily H TrittschuhDepartment of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA.
Jesse MezDepartment of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston University Medical Center, Boston, Massachusetts, USA.
Lindsay A FarrerDepartment of Neurology, Boston University Chobanian & Avedisian School of Medicine, Boston University Medical Center, Boston, Massachusetts, USA.
Katherine A GiffordVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University in St. Louis, St. Louis, Missouri, USA.
Jason HassenstabDepartment of Neurology and Department Psychological & Brain Sciences, Washington University in St Louis, St. Louis, Missouri, USA.
Adam C NajDepartment of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Li-San WangPenn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Sterling C JohnsonAlzheimer's Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin, USA.
Corinne D EngelmanAlzheimer's Disease Research Center, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin, USA.
Walter A KukullDepartment of Neurology, WashU Medicine, St. Louis, Missouri, USA.
C Dirk KeeneDepartment of Laboratory Medicine and Pathology, University of Washington, St. Seattle, Washington, USA.
Andrew J SaykinDepartment of Radiology and Imaging Services, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Michael L CuccaroJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Brian W KunkleJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Margaret A Pericak-VanceJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
Eden R MartinJohn P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, USA.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, St. Chicago, Illinois, USA.
Lisa L BarnesRush Alzheimer's Disease Center, Rush University Medical Center, St. Chicago, Illinois, USA.
Julie A SchneiderRush Alzheimer's Disease Center, Rush University Medical Center, St. Chicago, Illinois, USA.
William S BushCleveland Institute for Computational Biology, Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Jonathan L HainesCleveland Institute for Computational Biology, Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Richard MayeuxDepartment of Neurology, The Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center and The New York Presbyterian Hospital, New York, New York, USA.
Badri N VardarajanDepartment of Neurology, The Taub Institute for Research on Alzheimer's Disease and The Aging Brain, Columbia University Medical Center and The New York Presbyterian Hospital, New York, New York, USA.
Marilyn S AlbertDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Paul M ThompsonKeck School of Medicine, University of Southern California, Los Angeles, California, USA.
Angela L JeffersonVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Alzheimer's Disease Neuroimaging Initiative (ADNI)*Alzheimer's Disease Genetics Consortium (ADGC)The Alzheimer's Disease Sequencing Project (ADSP)
Paul K CraneDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Logan DumitrescuVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Derek B ArcherVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Timothy J HohmanVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Leslie S GaynorVanderbilt Memory & Alzheimer's Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID https://orcid.org/0000-0003-1121-4365
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MTranslational pharmacoepidemiology: neuroprotection and neurotoxicity of antihypertensives and strong anticholinergicsU19AG066567 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI Linda Kathleen McEvoy · 2021 to 2026
$80.4MSmartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5MThe natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5MSUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1MNational Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8MEPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3MMVP Data Integration into the ADSP Phenotype Harmonization ConsortiumU24AG074855 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CUCCARO, MICHAEL L, HOHMAN, TIMOTHY J · 2021 to 2025
$37.5MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Katherine P Rankin · 2019 to 2026
$36.9MResearch Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5MWisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6MUCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DOUGLAS R GALASKO · 2019 to 2026
$34.9MAlzheimer's AssociationAlzheimer's Drug Discovery FoundationAlzheimer's Therapeutic Research InstituteAraclon BiotechBioClinica, Inc.BiogenBristol-Myers Squibb CompanyCereSpir, Inc.CIHRCogstateElan Pharmaceuticals, Inc.Eli Lilly and CompanyEuroImmunF. Hoffmann-La Roche Ltd.following: AbbVieFujirebioGE HealthcareGenentech, Inc.Illinois Department of Public HealthIXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLC.Johnson & Johnson Pharmaceutical Research & Development LLCLaboratory for Neuro ImagingLumosityLundbeckMeso Scale Diagnostics, LLC.NeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS K01 AG073584NIA NIH HHS K24 AG046373NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG066546NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072959NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072973NIA NIH HHS P30 AG072975NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072978NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG086401NIA NIH HHS P30 AG086404NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG021155NIA NIH HHS R01 AG022018NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG027944NIA NIH HHS R01 AG028786NIA NIH HHS R01 AG037639NIA NIH HHS R01 AG054047NIA NIH HHS R01 AG056405NIA NIH HHS R01 AG059716NIA NIH HHS R01 AG064233NIA NIH HHS R01 AG067482NIA NIH HHS R01 AG079280NIA NIH HHS RF1 AG054074NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG052410NIA NIH HHS U01 AG068057NIA NIH HHS U19 AG066567NIA NIH HHS U24 AG056270NIA NIH HHS U24 AG072122NIA NIH HHS U24 AG074855NIH HHSNINDS NIH HHS UH2 NS100599NINDS NIH HHS UH3 NS100599Northern California Institute for Research and EducationNovartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingServierTakeda Pharmaceutical CompanyThe ADSP Phenotype Harmonization Consortiumthe Alzheimer's Disease Neuroimaging Initiative W81XWH-12-2-0012the National Institute of Biomedical Imaging and Bioengineeringthe National Institute on Agingthe Wisconsin Registry for Alzheimer's Prevention R01 AG0271761Transition TherapeuticsUniversity of Southern California P30 AG10161University of Southern California R01 AG15819
Abstract
introduction"SuperAgers" are oldest-old adults (ages 80+) whose memory performance more closely resembles middle-aged adults. The present study examined apolipoprotein E (APOE) allele frequency in non-Hispanic Black (NHB) and non-Hispanic White (NHW) SuperAgers compared to controls and Alzheimer's disease dementia cases.
methodsIn 18,080 participants from eight cohorts, harmonized clinical diagnostics and memory, executive function, and language domain scores were used to identify SuperAgers, cases, and controls across age-defined bins.
resultsNHW SuperAgers had significantly lower frequency of APOE-ε4 alleles and higher frequency of APOE-ε2 alleles compared to all cases and controls, including oldest-old controls. Similar patterns were found in a small yet substantial sample of NHB SuperAgers; however, not all comparisons with controls reached significance. DISCUSSION: We demonstrated strong evidence that APOE allele frequency relates to SuperAger status. Further research is needed with a larger sample of NHB SuperAgers to determine if mechanisms conferring cognitive resilience differ across race groups. HIGHLIGHTS: Apolipoprotein E (APOE) allele frequency differs between SuperAgers and cases APOE allele frequency differs between non-Hispanic White SuperAgers and controls The relationship of APOE and non-Hispanic Black SuperAger status is unclear.
Indexed as
AgingAlzheimer DiseaseApolipoproteins ECognitionAgedAged, 80 and overAllelesApolipoprotein E4Black or African AmericanExecutive FunctionFemaleGene FrequencyGenotypeHumansMaleNeuropsychological TestsApolipoprotein E4Apolipoproteins EAlzheimer's diseaseAPOE genotypecognitive agingcognitive resilienceSuperAgers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.